#1 Clinical Trials Search in Europe

Dosulepin Hydrochloride

Dosulepin Hydrochloride, a tricyclic antidepressant (TCA), is being studied in clinical trials for its effectiveness in treating various mental health conditions. This article explores two ongoing trials investigating the use of Dosulepin in patients with Somatic Symptom Disorder (SSD) and Depression. These studies aim to compare Dosulepin with other antidepressants and evaluate its impact on symptoms, quality of life, and biological markers associated with these conditions.

Table of Contents

What is Dosulepin?

Dosulepin, also known as Dosulepin Hydrochloride, is an antidepressant medication that belongs to the class of drugs called tricyclic antidepressants (TCAs)[1]. TCAs are a group of medications that have been used for many years to treat various mental health conditions, primarily depression.

Uses of Dosulepin

Dosulepin is primarily used to treat depression, particularly in cases where the patient experiences somatic symptoms[1]. Somatic symptoms are physical manifestations of depression, such as changes in appetite, sleep disturbances, or unexplained aches and pains. Specifically, Dosulepin is prescribed for:

  • Mild to moderate depressive episodes with somatic syndrome: This refers to cases of depression where the patient experiences both emotional and physical symptoms[1].

How Dosulepin Works

Dosulepin, like other tricyclic antidepressants, works by affecting certain chemicals in the brain called neurotransmitters. Specifically, it is believed to increase the levels of serotonin and norepinephrine, two neurotransmitters that play crucial roles in mood regulation[1].

Recent research has also focused on the effect of antidepressants like Dosulepin on neurotrophic factors. These are proteins that support the growth, survival, and function of brain cells. Some neurotrophic factors that may be affected by antidepressants include:

  • Nerve Growth Factor (NGF): This protein is important for the growth and maintenance of certain nerve cells[1].
  • Neurotrophin-3 (NT-3): This factor supports the survival of existing neurons and encourages the growth of new neurons and synapses[1].
  • Neurotrophin-4 (NT-4): This protein also plays a role in the growth and survival of neurons[1].

Dosage and Administration

The dosage of Dosulepin can vary depending on the individual patient’s needs and response to the medication. However, based on the clinical trial information provided, a typical dosage regimen might look like this:

  1. Starting dose: 25 mg per day[1].
  2. Gradual increase: The dose is typically increased gradually over a period of about 2 weeks[1].
  3. Target dose: The dose is usually increased up to 75 mg per day[1].
  4. Duration: Patients are typically continued on this dose for a minimum period of 6 weeks[1].

It’s important to note that this is a general guideline, and your doctor will prescribe the dosage that’s right for you based on your individual circumstances.

Current Research

Dosulepin is currently being studied as part of a broader investigation into how different types of antidepressants affect neurotrophic factors in patients with depression[1]. This research aims to better understand the biological mechanisms of depression and how antidepressants work to alleviate symptoms.

The study is comparing Dosulepin (a tricyclic antidepressant) with other types of antidepressants, including:

  • Sertraline: A selective serotonin reuptake inhibitor (SSRI)[1].
  • Venlafaxine: A serotonin-norepinephrine reuptake inhibitor (SNRI)[1].

The researchers are measuring changes in the levels of neurotrophic factors (NGF, NT-3, and NT-4) in patients’ blood over a 6-week period of treatment with these different antidepressants[1].

Potential Side Effects

While the provided clinical trial information doesn’t specifically list side effects of Dosulepin, it’s important to note that all medications can have potential side effects. Common side effects of tricyclic antidepressants like Dosulepin may include:

  • Dry mouth
  • Blurred vision
  • Constipation
  • Difficulty urinating
  • Drowsiness
  • Dizziness

Always consult with your healthcare provider about potential side effects and report any unusual symptoms you experience while taking this medication.

Aspect Somatic Symptom Disorder Trial Depression Trial
Primary Condition Somatic Symptom Disorder Depressive Episode
Dosulepin Dosage 25 mg/day in first week, 50 mg/day from second week 25 mg/day, gradually increased to 75 mg/day over 2 weeks
Comparison Drug Venlafaxine Sertraline and Venlafaxine
Treatment Duration 8 weeks Minimum 6 weeks
Primary Outcome Measure Change in PHQ-15 score Change in serum nerve growth factor
Secondary Measures Treatment response rate, serum cortisol, TNF-alpha levels, quality of life Changes in neurotrophin-3, neurotrophin-4, depression severity

FAQ

  • What is Dosulepin Hydrochloride? Dosulepin Hydrochloride is a tricyclic antidepressant (TCA) medication being studied for its potential in treating mental health conditions such as Somatic Symptom Disorder and Depression.
  • How is Dosulepin being used in the Somatic Symptom Disorder trial? In the SSD trial, Dosulepin is being compared to Venlafaxine. Patients start with a dose of 25 mg/day in the first week, which is then increased to a stable dose of 50 mg/day from the second week and continued for 8 weeks.
  • What are the main outcomes being measured in these trials? The trials are measuring changes in symptoms using questionnaires like PHQ-15 for SSD and Montgomery-Åsberg Depression Rating Scale for Depression. They also look at quality of life, treatment response rates, and biological markers such as serum cortisol and neurotrophic factors.
  • How long do the treatments in these trials last? In both trials, the treatment duration is a minimum of 6 to 8 weeks, allowing researchers to observe the effects of Dosulepin over an extended period.
  • Are there any side effects being monitored in these trials? Yes, the SSD trial specifically mentions using the Antidepressant Side-Effect Checklist (ASEC) to evaluate the incidence of treatment-emergent adverse events associated with the medications being studied.

Ongoing Clinical Trials on Dosulepin Hydrochloride

  • Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Germany Greece Italy Spain

Glossary

  • Somatic Symptom Disorder (SSD): A condition characterized by persistent physical complaints, often involving pain, along with excessive thoughts or behaviors related to these symptoms, which significantly disrupt daily functioning.
  • Tricyclic Antidepressant (TCA): A class of antidepressant medications that work by increasing levels of norepinephrine and serotonin in the brain to help improve mood.
  • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI): A type of antidepressant that increases levels of serotonin and norepinephrine in the brain by blocking their reabsorption.
  • Neurotrophins: Proteins that help with the growth, survival, and function of nerve cells, including brain cells. Examples include NGF, BDNF, NT-3, and NT-4.
  • Cortisol: A hormone produced by the adrenal glands in response to stress, often referred to as the 'stress hormone'.
  • TNF-alpha: Tumor Necrosis Factor-alpha, a protein involved in systemic inflammation and acute phase reaction.
  • PHQ-15: Patient Health Questionnaire-15, a self-administered questionnaire used to screen for somatic symptoms and their severity.
  • WHO-QOL BREF: World Health Organization Quality of Life Brief version, a questionnaire that assesses an individual's perception of their quality of life across various domains.
  • Montgomery-Åsberg Depression Rating Scale: A questionnaire used by healthcare professionals to measure the severity of depressive episodes in patients with mood disorders.

References

  1. https://clinicaltrials.gov/study/NCT03126188